APA (7th ed.) Citation

Alfaro, A. O. V., Vargas, H. C. G., Díaz, J. M., Pinto, J. A., Cambero, D. C. G., Cuellar, E. H., . . . Ponce-Campos, S. D. (2025). Anti-IL-5 and anti-IL-5 receptor therapy significantly improves quality of life and FEV1 values in patients with severe asthma. Allergy, Asthma & Clinical Immunology, 21(1), 1. https://doi.org/10.1186/s13223-025-00979-y

Chicago Style (17th ed.) Citation

Alfaro, Anaiza Odalis Villalobos, et al. "Anti-IL-5 and Anti-IL-5 Receptor Therapy Significantly Improves Quality of Life and FEV1 Values in Patients with Severe Asthma." Allergy, Asthma & Clinical Immunology 21, no. 1 (2025): 1. https://doi.org/10.1186/s13223-025-00979-y.

MLA (9th ed.) Citation

Alfaro, Anaiza Odalis Villalobos, et al. "Anti-IL-5 and Anti-IL-5 Receptor Therapy Significantly Improves Quality of Life and FEV1 Values in Patients with Severe Asthma." Allergy, Asthma & Clinical Immunology, vol. 21, no. 1, 2025, p. 1, https://doi.org/10.1186/s13223-025-00979-y.